Cardiac Valvular Dysplasia, X-Linked

Cardiac valvular dysplasia, X-linked is a rare inherited heart condition where one or more heart valves are abnormally formed and become thick, soft (myxomatous), and leaky or narrowed over time. The problem starts during development of the valves before birth. Most families with this condition have a change (mutation) in a gene called FLNA (filamin A) on the X chromosome. Because it is X-linked, boys/men (who have only one X chromosome) often have more severe disease than girls/women (who have two X chromosomes). The valves most often affected are the mitral and aortic valves, but any valve can be involved. MedlinePlus+2informatics.jax.org+2

X-linked cardiac valvular dysplasia is a rare genetic condition where one or more heart valves become abnormally thick, floppy, and “myxomatous” (gel-like). These valve changes can make the leaflets leak (regurgitation) or narrow (stenosis). The mitral and aortic valves are most often affected. The condition is X-linked and is caused by changes (variants) in the FLNA gene, which encodes filamin-A, a protein that helps cells keep their shape and anchor to the surrounding support matrix. Because the gene is on the X chromosome, males tend to be affected more severely, while females may have milder findings. People can be diagnosed from before birth to adulthood, sometimes after years of silent progression. MedlinePlus+2MedlinePlus+2

FLNA is a scaffolding protein that links the cell’s skeleton to signaling pathways (like ERK and SMAD/TGF-β) that control how valve tissue grows and remodels. Mutations disturb that balance, leading to myxomatous degeneration, thickened, elongated leaflets, and sometimes shortened or thickened chordae tendineae, especially in the mitral valve. The result is valve prolapse and leakage. PMC+2anatomypubs.onlinelibrary.wiley.com+2

This condition is X-linked. Males with the FLNA variant are typically more severely affected (often with multiple valves needing surgery), while females may have milder or later disease due to X-inactivation (some cells use the healthy copy). In large pedigrees, men show earlier and more severe valve problems; women can show variable symptoms from none to significant disease. OUP Academic+1

FLNA makes a structural protein that helps heart valve cells sense and respond to mechanical forces. When FLNA does not work correctly, the valve tissue weakens, swells with gelatin-like material (myxoid change), and the leaflets can prolapse or fail to seal. Over time this leads to regurgitation (back-leak of blood) and sometimes stenosis (narrowing). PMC+1

Other names

This condition appears in the medical literature under several names. All of the following describe the same disease spectrum tied to FLNA mutations:

• X-linked cardiac valvular dysplasia (XCVD)

• FLNA-related X-linked myxomatous valvular dystrophy

• Filamin A–related myxomatous mitral valve dystrophy

• X-linked myxomatous valvular disease

• Database terms include: OMIM: 314400, Orphanet: 555877, MONDO:0010753, UMLS/MedGen concepts for XCVD. NCBI+3Orpha+3informatics.jax.org+3

XCVD is rare and reported mostly in families. Public rare-disease registries estimate far fewer than 1,000 affected individuals in the U.S., recognizing that many cases go undiagnosed or are labeled as “familial mitral valve prolapse.” rarediseases.info.nih.gov

---

Types

Because “types” are not strictly formal for XCVD, doctors often group it by what valves are involved, how the valve behaves, and when it shows up:

1. By valve involvement

• Mitral-predominant XCVD – classic form with mitral valve prolapse (MVP) or regurgitation; chordae may be shortened rather than ruptured. PMC

• Aortic involvement – thickened aortic leaflets causing aortic regurgitation or bicuspid-like changes; may coexist with mitral disease. ScienceDirect+1

• Polyvalvular disease – more than one valve (mitral, aortic, tricuspid, pulmonary) affected in the same person, often in males. BioMed Central

2. By functional effect

• Regurgitant type – leaflets billow or fail to coapt, causing backflow. MedlinePlus

• Stenotic type – thickening and restricted opening cause narrowing (less common). malacards.org

• Mixed type – both regurgitation and stenosis. informatics.jax.org

3. By age at recognition

• Congenital/infant-detected – murmurs or valve thickening on newborn echo. rarediseases.info.nih.gov

• Childhood/adult-onset – progressive myxomatous changes lead to prolapse and regurgitation recognized later. OUP Academic

---

Causes

Although FLNA mutation is the root cause, the following factors describe which gene changes and why the disease looks different person to person:

1. Pathogenic variants in FLNA – the primary, necessary cause in familial XCVD. AHA Journals

2. Missense mutations (e.g., G288R, V711D) in key domains alter protein function and valve development. SpringerLink

3. In-frame deletions/duplications that disturb FLNA’s rod domains and cell signaling. ScienceDirect

4. Loss-of-function variants affecting FLNA’s ability to anchor the cytoskeleton to signaling hubs. anatomypubs.onlinelibrary.wiley.com

5. X-linked inheritance pattern – males (hemizygous) express the defect fully, driving more severe disease. PMC

6. Skewed X-inactivation in females – can increase or decrease disease expression depending on which X is active. (Inference from X-linked biology discussed in reviews.) OUP Academic

7. Polyvalvular susceptibility – FLNA variants can affect multiple valves formed from endocardial cushions. BioMed Central

8. Disrupted mechanosensing – faulty FLNA blunts normal responses to blood flow and stretch, weakening leaflet structure. PMC

9. Imbalanced ERK/SMAD/TGF-β signaling – shifts matrix turnover toward myxomatous change. anatomypubs.onlinelibrary.wiley.com

10. Abnormal collagen/elastin network in leaflets due to altered cytoskeletal signaling. PMC

11. Shortened or thickened chordae from altered extracellular-matrix remodeling. PMC

12. Developmental errors in valve primordia (endocardial cushion morphogenesis). PMC

13. Genetic modifiers – other genes may influence severity (suggested in familial variability). OUP Academic

14. Sex-related differences in expression and severity (male > female). PMC

15. Variant location within FLNA – proximal rod domain variants often reported in XCVD families. Rev Esp Cardiolog

16. Somatic mosaicism in a parent can seed familial transmission with variable expression. (Described across FLNA spectrum.) SpringerLink

17. Associated syndromic spectrum of FLNA – some families show connective-tissue/vascular features, underscoring shared biology. Nature

18. Hemodynamic stress over time – worsens regurgitation in weakened leaflets. (General mechanism discussed in FLNA/MVP reviews.) OUP Academic

19. Progressive myxomatous degeneration – the hallmark tissue change that advances with age. PMC

20. Rare non-FLNA loci under study – but FLNA is the clearly established gene for isolated X-linked valvulopathy. AHA Journals

---

Symptoms and signs

Symptoms depend on which valve is affected and how severe the leak or narrowing is.

1. Heart murmur picked up by a doctor—often the first clue. Rev Esp Cardiolog

2. Shortness of breath, first on exertion, later possibly at rest if regurgitation is significant. MedlinePlus

3. Fatigue and low exercise tolerance due to inefficient blood flow. MedlinePlus

4. Palpitations or a “racing” heartbeat, sometimes from rhythm problems that can accompany valve disease. MedlinePlus

5. Chest discomfort with exertion in advanced cases. MedlinePlus

6. Swelling of legs or ankles if heart failure develops from severe regurgitation. NCBI

7. Dizziness or fainting (rare), more with significant aortic valve disease. MedlinePlus

8. Cough, especially at night when fluid backs up into lungs (advanced). NCBI

9. Rapid breathing or feeding difficulty in infants with significant valve disease. rarediseases.info.nih.gov

10. Poor weight gain in infants if heart work is high. rarediseases.info.nih.gov

11. Exercise intolerance in children (tires easily in play). MedlinePlus

12. Head pounding or wide pulse pressure in aortic regurgitation. NCBI

13. New or louder murmur during illness or growth spurts as hemodynamics change. (General valve physiology summarized by genetics overviews.) MedlinePlus

14. Symptoms vary in females—can be mild or absent for years due to X-inactivation. PMC

15. Family history of valve disease or early valve surgery is a key “symptom” clue for clinicians. ScienceDirect

---

Diagnostic tests

A) Physical examination

1. Careful cardiac auscultation – Doctors listen for clicks (mitral prolapse) and murmurs of regurgitation or stenosis; dynamic changes with position can help identify which valve is affected. MedlinePlus

2. Pulse and blood-pressure assessment – Bounding pulses/wide pulse pressure suggest aortic regurgitation; low pulse volume can suggest stenosis or heart failure. NCBI

3. Jugular venous and lung exam – Neck vein distention and lung crackles suggest fluid overload from advanced regurgitation. NCBI

4. Peripheral edema check – Leg/ankle swelling can indicate right-sided strain or overall heart failure from severe valve leak. NCBI

5. Family history and pedigree – Building a three-generation family tree helps reveal X-linked inheritance (affected males, variable females). ScienceDirect

B) Manual bedside maneuvers

6. Squat-to-stand and handgrip – Simple maneuvers change afterload/preload and can make murmurs louder/softer, helping distinguish regurgitation vs prolapse behavior. MedlinePlus

7. Valsalva maneuver – Brief straining reduces venous return and may accentuate certain prolapse clicks, offering clues to mitral leaflet behavior. MedlinePlus

8. Postural changes (supine to sitting/left lateral) – Can bring out mid-systolic clicks of MVP or change murmur timing. MedlinePlus

9. Six-minute walk test – Simple functional gauge; falling tolerance can reflect valve severity or heart failure progression over time. (Functional monitoring adjunct.) MedlinePlus

C) Lab and pathological tests

10. Genetic testing for FLNA – Targeted sequencing or gene panels confirm diagnosis and guide family screening; FLNA is the established gene for X-linked isolated valvulopathy. AHA Journals

11. Family (cascade) testing – Testing at-risk relatives (especially males) finds early disease and informs surveillance. OUP Academic

12. BNP/NT-proBNP – Blood markers can support detection of hemodynamic strain in significant regurgitation or heart failure, complementing imaging. (General heart-failure practice applied to valve disease.) MedlinePlus

13. Pathology of excised valves (if surgery) – Shows myxomatous degeneration and leaflet thickening typical of FLNA-related disease. PMC

D) Electrodiagnostic

14. 12-lead ECG – Looks for chamber enlargement (e.g., left atrium from mitral regurgitation) and rhythm issues that can accompany valve disease. MedlinePlus

15. Ambulatory ECG (Holter/patch) – Captures intermittent arrhythmias or palpitations in symptomatic patients. MedlinePlus

16. Exercise ECG – Assesses exertional symptoms and heart-rate/arrhythmia behavior with valve lesions. MedlinePlus

E) Imaging

17. Transthoracic echocardiography (TTE) – The main test: shows leaflet thickness, prolapse, regurgitation jets, and measures chamber size and pumping function. It is essential for baseline and follow-up. OUP Academic

18. Transesophageal echo (TEE) – Gives high-detail views of valves and chordae, useful pre-surgery or when TTE is limited. OUP Academic

19. Doppler (color/spectral) echo – Quantifies regurgitation severity and estimates valve gradients if stenosis is present. OUP Academic

20. 3D echocardiography – Maps leaflet scallops and annulus geometry for surgical planning in complex XCVD. OUP Academic

21. Fetal echocardiography – Can detect thickened or dysfunctional valves before birth in high-risk pregnancies (known FLNA variant). rarediseases.info.nih.gov

22. Cardiac MRI – Precise volumes and regurgitant fraction; tissue characterization complements echo findings. OUP Academic

23. Cardiac CT – Helpful when echo windows are poor and for pre-operative anatomy; also evaluates aortic root if needed. OUP Academic

24. Cardiac catheterization – Rarely needed only for unclear cases or when planning surgery and coronary assessment is required. OUP Academic

Non-pharmacological treatments (therapies & “other”)

1. Regular, guideline-timed echocardiography: Purpose—catch progression early; Mechanism—objective measurements trigger timely treatment. JACC

2. Genetic counseling & family screening: Purpose—identify at-risk relatives; Mechanism—test for FLNA and arrange early echo follow-up. NCBI

3. Heart-team care at a valve center: Purpose—expert decisions; Mechanism—multidisciplinary review (cardiology, imaging, surgery, genetics). Rev Esp Cardiolog

4. Dental hygiene & routine dental care: Purpose—lower endocarditis risk; Mechanism—reduces everyday oral bacteremia that can seed valves. AHA Journals

5. Activity guidance: Purpose—stay active safely; Mechanism—moderate aerobic exercise; avoid extreme isometric strain in severe valve disease. JACC

6. Salt-aware eating pattern: Purpose—limit fluid retention; Mechanism—less sodium reduces congestion in significant regurgitation/HF. AHA Journals

7. Weight management: Purpose—reduce workload; Mechanism—healthy weight improves blood pressure and symptoms. American College of Cardiology

8. Smoking cessation & alcohol moderation: Purpose—protect heart rhythm and vessels; Mechanism—cuts AF risk and BP strain. AHA Journals

9. Pregnancy planning with cardio-obstetrics: Purpose—safer pregnancy; Mechanism—pre-pregnancy echo and plan for monitoring. JACC

10. Vaccinations (influenza/COVID-19/pneumococcal as indicated): Purpose—lower infection-related decompensation; Mechanism—prevent systemic stressors. JACC

11. Sleep apnea screening if symptomatic: Purpose—improve BP/rhythm control; Mechanism—treating OSA reduces afterload/AF burden. JACC

12. Structured cardiac rehab (when deconditioned): Purpose—restore stamina; Mechanism—supervised exercise within safe hemodynamic ranges. JACC

13. Diuretic self-care education: Purpose—recognize fluid signs; Mechanism—daily weights, call team if >2 kg gain in 3 days. JACC

14. Blood pressure control (non-drug basics): Purpose—reduce valve stress; Mechanism—diet/activity/sleep lower afterload. AHA Journals

15. Limit heavy stimulants (excess caffeine/energy drinks): Purpose—reduce palpitations; Mechanism—lower trigger burden for arrhythmias. JACC

16. Infection vigilance: Purpose—early endocarditis rule-out; Mechanism—prompt cultures/assessment before antibiotics if fever/unwell. www.heart.org

17. Travel & altitude planning for advanced disease: Purpose—avoid sudden decompensation; Mechanism—plan oxygen/medical contacts as needed. JACC

18. Avoid unnecessary invasive procedures when unstable: Purpose—reduce complications; Mechanism—time procedures with the heart team. JACC

19. Psychological support: Purpose—reduce anxiety/palpitations feedback loop; Mechanism—coping skills and adherence support. JACC

20. Surgery/structural intervention education: Purpose—prepare early; Mechanism—understand signs when repair/replacement is beneficial. JACC

---

Drug treatments

There is no pill that “fixes” the FLNA mutation or the malformed valve. Medicines are used to treat problems caused by the valve (heart failure symptoms, irregular rhythm, blood clots) while doctors plan the right repair or replacement. Doses below are representative adult ranges—must be personalized for age, kidney function, rhythm, and pregnancy status.

1. Furosemide (loop diuretic): Typical adult start 20–40 mg once/twice daily, titrate; Purpose—reduce congestion; Mechanism—kidney loop diuresis; Side effects—electrolyte loss, dehydration. FDA Access Data

2. Torsemide (loop diuretic): 10–20 mg daily; better oral bioavailability; similar cautions as furosemide. FDA Access Data

3. Spironolactone (MRA): 12.5–25 mg daily; Purpose—HF benefit and potassium sparing; Side effects—hyperkalemia, gynecomastia. FDA Access Data

4. Eplerenone (MRA): 25–50 mg daily; fewer endocrine effects; watch K⁺/CYP3A4 interactions. FDA Access Data+1

5. ACE inhibitor (e.g., Enalapril/Lisinopril): start low (e.g., enalapril 2.5–5 mg bid) for HF/afterload; cough, hyperkalemia possible. (Representative label class; use per BP and renal status.) JACC

6. ARB (e.g., Valsartan): alternative to ACEI; dose per label; avoid in pregnancy. JACC

7. Sacubitril/valsartan (ARNI): 24/26–97/103 mg bid (transition rules from ACEI apply); improves HF outcomes; avoid in pregnancy; watch for angioedema. FDA Access Data+1

8. Metoprolol succinate (beta-blocker): 12.5–25 mg daily titrated; Purpose—rate control, HF; Side effects—bradycardia, fatigue. (Class exemplar; HF label.) JACC

9. Carvedilol (beta-blocker): start 3.125–6.25 mg bid; improves survival in HF; monitor BP/HR. FDA Access Data+1

10. Ivabradine: for symptomatic HFrEF in sinus rhythm ≥70 bpm despite beta-blocker; 5–7.5 mg bid; risk of bradycardia/visual phenomena. FDA Access Data

11. Digoxin: 0.125–0.25 mg daily (lower in elderly/renal); Purpose—rate control and symptom relief; narrow therapeutic window. FDA Access Data+1

12. Amiodarone: rhythm control for atrial/ventricular arrhythmias when needed; complex dosing; monitor thyroid/liver/lung. FDA Access Data+1

13. Sotalol: rhythm control (AF/VT) in selected patients; needs QT monitoring and renal dosing. FDA Access Data+1

14. Dofetilide: rhythm control for AF with mandatory in-hospital initiation and QT monitoring. FDA Access Data

15. Warfarin: anticoagulation for AF or prosthetic mechanical valves; dose to INR target; many interactions. FDA Access Data+1

16. Apixaban: anticoagulation for non-valvular AF (not for mechanical valves); common dose 5 mg bid; bleeding risk. FDA Access Data+1

17. Rivaroxaban: anticoagulation for non-valvular AF (not for mechanical valves); dose per kidney function; bleeding risk. FDA Access Data+1

18. Empagliflozin (SGLT2 inhibitor): reduces HF hospitalization/death regardless of diabetes; 10 mg daily; monitor volume/Kidney function. FDA Access Data+1

19. Dapagliflozin (SGLT2 inhibitor): similar HF benefits; 10 mg daily; monitor volume/Kidney function. FDA Access Data+1

20. Short-term antibiotics for proven infective endocarditis (e.g., beta-lactams for viridans streptococci) per culture—not routine prophylaxis except highest-risk groups. AHA Journals+1

Important safety notes:
• Direct oral anticoagulants (DOACs) are contraindicated in mechanical valves; warfarin is used instead. Use DOACs cautiously and only for non-valvular AF or other labeled indications. JACC
• ACEI/ARB/ARNI are harmful in pregnancy—women of child-bearing potential need counseling. FDA Access Data

---

Dietary molecular supplements

There are no supplements proven to reverse XLCVD. General heart-healthy eating patterns have the best evidence. If people choose supplements, decisions should be individualized and checked for drug interactions (e.g., warfarin). Highlights:

1. Omega-3 from food first (fish, nuts); supplements may help triglycerides, but diet pattern is key. AHA Journals

2. Plant-based dietary pattern emphasis (fiber, legumes, nuts) supports blood pressure and weight. AHA Journals

3. Limited sodium (<~1.5–2 g/day in HF unless otherwise directed) supports symptom control. AHA Journals

4. Adequate potassium from foods (unless on MRAs/renal disease); supports BP. AHA Journals

5. Magnesium (food-based) may reduce ectopy in deficiency; supplement only if low, to avoid diarrhea or interactions. AHA Journals

6. Vitamin D—replete if deficient for general health; no valve-specific benefit proven. Dietary Guidelines

7. Coenzyme Q10—mixed evidence for HF symptoms; discuss with clinician if considered. AHA Journals

8. Avoid stimulant/herbal mixes that can raise heart rate or interact with anticoagulants (e.g., St John’s wort). JACC

9. Limit alcohol—helps rhythm control and blood pressure. AHA Journals

10. Focus on overall pattern (AHA 2021), not single pills—this has the strongest cardiovascular evidence. AHA Journals+1

---

Immunity-booster/regenerative/stem-cell drugs

There are no FDA-approved stem-cell or “regenerative” drugs for repairing myxomatous valve tissue in XLCVD. The FDA has repeatedly warned the public about unapproved stem-cell/exosome products marketed for heart disease and many other conditions because of serious harms (infection, blindness, tumor formation). If you encounter clinics offering these treatments for valve disease, avoid them and consult qualified cardiology/genetics teams. Pew Charitable Trusts+3U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3

---

Surgeries/procedures

1. Mitral valve repair (preferred when feasible): Surgeons reshape leaflets, repair/replace chordae, and support the ring (annuloplasty) to stop leakage while preserving the native valve—often best durability in myxomatous disease. JACC

2. Aortic valve repair or replacement: If stenosis/regurgitation is severe, replacement with mechanical (durable, requires warfarin) or bioprosthetic (less durable, typically no long-term warfarin) valve; decision individualized. JACC

3. Tricuspid/pulmonic repair when multivalvular disease is significant; often done during left-sided surgery if indicated. JACC

4. Transesophageal echo–guided surgery: TEE provides precise leaflet/chordal views and confirms results in the operating room. STS

5. Arrhythmia procedures (e.g., AF ablation) or pacemaker/ICD in selected patients with rhythm or conduction problems. JACC

---

Preventions

1. Know your family risk and consider FLNA testing with counseling. NCBI

2. Keep scheduled echocardiograms even if you feel well. JACC

3. Brush, floss, and see a dentist regularly; this reduces endocarditis risk. AHA Journals

4. Follow a heart-healthy eating pattern (AHA 2021). AHA Journals

5. Maintain healthy blood pressure and body weight. American College of Cardiology

6. Quit smoking and limit alcohol. AHA Journals

7. Take medications exactly as prescribed and check for interactions. JACC

8. Vaccinate as recommended to avoid infection-triggered decompensation. JACC

9. Plan pregnancy with your team if you have significant valve disease. JACC

10. Use expert centers for surgery when indicated. Rev Esp Cardiolog

---

When to see a doctor (or urgent care)

See a cardiologist promptly for: new or worsening shortness of breath, reduced exercise capacity, chest pain/pressure, rapid or irregular heartbeat, fainting, leg swelling, fever with a history of valve disease, or new pregnancy with known valve problems. Seek urgent care for severe breathlessness, fainting, crushing chest pain, or suspected endocarditis (fever + murmur). These features can signal progression to severe regurgitation/stenosis, heart failure, or arrhythmia that needs immediate evaluation. JACC+1

---

What to eat and what to avoid

Eat mostly: vegetables, fruits, whole grains, beans/lentils, nuts/seeds, fish/seafood, and unsweetened low-fat dairy as desired; cook with liquid plant oils (olive/canola). Limit: sodium (salt), added sugars, refined grains, ultra-processed foods, and heavy saturated fats; keep alcohol modest or avoid it. The overall pattern matters more than any single “superfood,” and it supports blood pressure, weight, and rhythm control while you and your team monitor the valves. AHA Journals+1

---

FAQs

1) Is there a cure?
Not a pill. When disease becomes severe or symptomatic, surgical repair or replacement is the definitive treatment; medicines manage symptoms and risks. JACC

2) Can diet or supplements fix the valve?
No. A heart-healthy diet improves overall heart status but doesn’t rebuild valve tissue. Avoid unproven “stem-cell” or “regenerative” products. AHA Journals+1

3) Do all carriers need surgery?
No. Many have mild disease. Regular echo follow-up guides timing. JACC

4) What’s special about X-linked inheritance?
Males (one X) are typically more severely affected; females (two Xs) can show milder or variable features due to X-inactivation. MedlinePlus

5) Which valves are most affected?
Usually mitral and aortic; sometimes multiple valves. MedlinePlus

6) Are antibiotics needed before dental work?
Only for people at highest risk; good daily dental care is far more important. Ask your cardiologist/dentist using the 2021 AHA guidance. AHA Journals+1

7) Can I exercise?
Yes—moderate aerobic exercise is encouraged unless your team says otherwise; avoid extreme strain if your valve disease is severe. JACC

8) What about pregnancy?
Plan ahead with cardio-obstetrics; many do well with close monitoring, but regurgitation can worsen during pregnancy due to higher blood volume. JACC

9) Is arrhythmia common?
Atrial fibrillation can occur with significant regurgitation or enlarged atria; treatment may include rate/rhythm control and sometimes anticoagulation. JACC

10) How often should I have an echo?
It depends on stage and symptoms; your cardiologist follows ACC/AHA intervals (e.g., from annually to every few years). JACC

11) What is the role of MRI/CT?
CMR precisely measures regurgitation and ventricular size; CT helps aortic and structural planning when needed. ASE

12) Are DOACs safe with mechanical valves?
No—warfarin is used for mechanical valves; DOACs are for non-valvular AF or other labeled uses. JACC

13) Could endocarditis be the first sign?
Rarely. If you have fever plus a murmur or valve disease, seek care before antibiotics so blood cultures can be drawn. www.heart.org

14) Will valve repair last?
In experienced centers, mitral repair for myxomatous disease often has excellent durability, but outcomes depend on anatomy and surgical expertise. JACC

15) Should my relatives be checked?
Yes—genetic counseling/testing and screening echocardiography for at-risk family members are recommended. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 11, 2025.

PDF Documents For This Disease Condition References